Blue rubber bleb nevus syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 8: | Line 8: | ||
* [[Interferon-beta]] | * [[Interferon-beta]] | ||
* [[Octreotide]] | * [[Octreotide]] | ||
* [[Sirolimus]] <ref name="pmid27820137">{{cite journal |vauthors=Ünlüsoy Aksu A, Sari S, Eğritaş Gürkan Ö, Dalgiç B |title=Favorable Response to Sirolimus in a Child With Blue Rubber Bleb Nevus Syndrome in the Gastrointestinal Tract |journal=J. Pediatr. Hematol. Oncol. |volume=39 |issue=2 |pages=147–149 |date=March 2017 |pmid=27820137 |doi=10.1097/MPH.0000000000000681 |url=}}</ref> | |||
* [[Iron]] supplementation | * [[Iron]] supplementation | ||
* [[Blood transfusions]] | * [[Blood transfusions]] | ||
Revision as of 18:05, 20 December 2018
Overview
The mainstay of treatment for blue rubber bleb nevus syndrome is interferon-beta, octreotide, iron supplementation and blood transfusions.
Medical Therapy
- Pharmacologic medical therapies for blue rubber bleb nevus syndrome include:[1]
- Interferon-beta
- Octreotide
- Sirolimus [2]
- Iron supplementation
- Blood transfusions
- Corticosteroids
- Propranolol
- Thalidomide
|
Blue rubber bleb nevus syndrome Microchapters |
|
Differentiating Blue Rubber Bleb Nevus Syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Blue rubber bleb nevus syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Blue rubber bleb nevus syndrome medical therapy |
|
Directions to Hospitals Treating Blue rubber bleb nevus syndrome |
|
Risk calculators and risk factors for Blue rubber bleb nevus syndrome medical therapy |
References
- ↑ Agnese M, Cipolletta L, Bianco MA, Quitadamo P, Miele E, Staiano A (April 2010). "Blue rubber bleb nevus syndrome". Acta Paediatr. 99 (4): 632–5. doi:10.1111/j.1651-2227.2009.01608.x. PMID 19958301.
- ↑ Ünlüsoy Aksu A, Sari S, Eğritaş Gürkan Ö, Dalgiç B (March 2017). "Favorable Response to Sirolimus in a Child With Blue Rubber Bleb Nevus Syndrome in the Gastrointestinal Tract". J. Pediatr. Hematol. Oncol. 39 (2): 147–149. doi:10.1097/MPH.0000000000000681. PMID 27820137.